F-652

BIOLOGICAL3 trials

Sponsors

Mayo Clinic, EVIVE Biotechnology

Conditions

Alcoholic HepatitisCOVID-19 PneumoniaCovid19

Phase 1

Use of F-652 in Patients With Alcoholic Hepatitis

CompletedNCT02655510

Mayo ClinicAlcoholic Hepatitis

Start: 2016-02-29End: 2018-06-30Updated: 2019-09-09

Phase 2

Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

TerminatedNCT04498377

EVIVE BiotechnologyCovid19

Start: 2021-01-26End: 2021-03-24Updated: 2023-12-21

Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia

WithdrawnNCT05205668

EVIVE BiotechnologyCOVID-19 Pneumonia

Start: 2022-04-08End: 2023-04-08Updated: 2023-10-02